Hormonal
Administering semaglutide to US adults with type 2 diabetes who meet SUSTAIN-6 trial eligibility criteria prevents approximately 75,681 primary composite cardiovascular events annually.
If you have Type 2 Diabetes and meet specific risk criteria (age over 50 with heart/kidney issues, or over 60 with additional risk factors), asking your doctor about semaglutide could potentially prevent tens of thousands of major heart events in your demographic group annually. The medication is a weekly injection that has been shown to significantly lower the risk of heart attack, stroke, and cardiovascular death in clinical trials.
We estimated 75,681 primary outcome CVD events... could be prevented annually if eligible T2DM subjects were on semaglutide.
Why this rating
Based on extrapolation of a high-quality randomized controlled trial (SUSTAIN-6) to a large population dataset (NHANES), though subject to demographic differences.
Source
US eligibility and preventable cardiovascular disease events from semaglutide in type 2 diabetes
Hridhay Karthikeyan et al. · Diabetes and Vascular Disease Research · 2025
DOI 10.1177/14791641251376551
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →